NEW YORK – Telo Genomics said Friday it will collaborate with Mayo Clinic on clinical studies to evaluate and validate the company's proprietary telomere analytics as a prognostic solution for multiple myeloma.
The studies were designed to include two retrospective phases, with the potential of a third prospective phase. The first phase of the studies is expected to launch in the first quarter of 2020.
For each phase, Telo's telomere analytics will be used to predict the progression of multiple myeloma precursors to full stage multiple myeloma and predict patient responses to first-line therapy at the point of diagnosis. The studies will be led by Shaji Kumar at the Mayo Clinic in Rochester, Minnesota.
"These studies are foundational to advance Telo-MM tests towards commercialization," Telo Genomics CEO Sherif Louis said in a statement. The company performs quantitative analysis of telomeres with a particular focus on liquid biopsy diagnostics and prognostics. It uses TeloView, a software platform, to quantify specific features of a patient's telomeres in 3-D.